Automate Your Wheel Strategy on CRDF
With Tiblio's Option Bot, you can configure your own wheel strategy including CRDF - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRDF
- Rev/Share 0.0064
- Book/Share 0.8809
- PB 2.8492
- Debt/Equity 0.0202
- CurrentRatio 4.4211
- ROIC -0.9087
- MktCap 166980006.0
- FreeCF/Share -0.6294
- PFCF -3.988
- PE -3.2725
- Debt/Assets 0.0156
- DivYield 0
- ROE -0.7795
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CRDF | Ladenburg Thalmann | -- | Buy | -- | $19 | July 8, 2025 |
| Initiation | CRDF | Jefferies | -- | Hold | -- | $3.5 | June 24, 2025 |
| Initiation | CRDF | Craig Hallum | -- | Buy | -- | $8 | Sept. 6, 2024 |
News
Cardiff Oncology: Data Update Resolves Some Signals
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Positive
Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, reflecting typical regression to the mean and leaving some questions unanswered until the next update in Q1 2026. CRDF's cash position is stable for now, but a future financing need is likely as the company advances toward a pivotal phase 3 trial.
Read More
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Negative
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.
Read More
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Cardiff Oncology: Buying The First-Line Onvansertib Strategy
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Cardiff Oncology's onvansertib shows promise as a first-in-class PLK1 inhibitor for first-line RAS-mutated metastatic colorectal cancer, potentially redefining standard-of-care and achieving blockbuster status. Onvansertib's synergy with bevacizumab and promising clinical data support its pivot to first-line treatment, with potential peak global sales of $1.2B to $2B annually. Despite strong prospects, CRDF faces risks including clinical/regulatory hurdles, market competition, and financial challenges, necessitating potential dilutive funding for Phase III trials and commercialization.
Read More
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Andy Hsieh - William Blair Robert Burns - H.C. Wainwright Albert Lowe - Craig-Hallum Operator Welcome to the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call.
Read More
About Cardiff Oncology, Inc. (CRDF)
- IPO Date 2004-07-27
- Website https://www.cardiffoncology.com
- Industry Biotechnology
- CEO Mark Erlander
- Employees 32